Tharimmune (NASDAQ:THAR) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Tharimmune (NASDAQ:THAR) from a hold rating to a sell rating in a research note published on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tharimmune in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tharimmune presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

Tharimmune Stock Down 0.3%

Shares of Tharimmune stock opened at $2.87 on Friday. The firm has a market capitalization of $16.94 million, a P/E ratio of -0.47 and a beta of 1.41. The company has a 50 day moving average price of $3.33 and a 200 day moving average price of $2.10. Tharimmune has a 52 week low of $0.95 and a 52 week high of $9.08.

Tharimmune (NASDAQ:THAR) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.06).

Institutional Investors Weigh In On Tharimmune

An institutional investor recently bought a new position in Tharimmune stock. Franklin Resources Inc. acquired a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 45,000 shares of the company’s stock, valued at approximately $88,000. Franklin Resources Inc. owned 1.07% of Tharimmune at the end of the most recent reporting period. 1.16% of the stock is currently owned by institutional investors.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).